Literature DB >> 27663361

5-aza-2'-deoxycytidine Inhibits the Proliferation of Lung Fibroblasts in Neonatal Rats Exposed to Hyperoxia.

Shimeng Zhao1, Meiling Cao1, Hongmin Wu1, Yu Hu2, Xindong Xue3.   

Abstract

BACKGROUND: A persistent increase in the number of lung fibroblasts (LFs) is found in the interstitium of the lungs of infants with bronchopulmonary dysplasia (BPD), which leads to lung fibrosis. P16 methylation plays an important role in the pathogenesis of BPD. 5-aza-2'-deoxycytidine (5-aza-CdR) is a major methyltransferase-specific inhibitor. This study investigated the effects of 5-aza-CdR on LFs in vitro from a hyperoxia-induced lung fibrosis model in newborn rats.
METHODS: Methylation-specific polymerase chain reaction (PCR) and Western blotting were performed to determine P16 gene methylation status and protein expression after LFs were treated with 0 μmol/L, 0.5 μmol/L, 1.0 μmol/L, and 5.0 μmol/L 5-aza-CdR for 120 hours. Proliferation was assessed by an MTT assay after LFs were treated with 0 μmol/L, 0.5 μmol/L, 1.0 μmol/L, and 5.0 μmol/L 5-aza-CdR for 24 hours, 48 hours, 72 hours, 96 hours, and 120 hours. At the final time point, cells were also analyzed by flow cytometry to identify any change in their cell cycle profiles.
RESULTS: A methylated P16 gene promoter was detected in hyperoxia LFs. Following treatment with 5-aza-CdR, partial methylation and demethylation was detected. The expression protein's level of the P16 gene was significantly higher in the 5.0 μmol/L 5-aza-CdR-treated group compared with that in the control group (p < 0.01). The cell growth rate at each tested time point was lower in the 5-aza-CdR-treated group compared with that in the control group after 72 hours (p < 0.01). Flow cytometry revealed that the cells in the 1.0 μmol/L and 5.0 μmol/L 5-aza-CdR-treated groups were apparently arrested in the G0/G1 phase and that the number of cells in the S phase was significantly lower than the control group (p < 0.01).
CONCLUSION: 5-aza-CdR inhibits the growth of the LFs in hyperoxia-induced neonatal BPD rats in vitro by demethylating the P16 gene.
Copyright © 2016. Published by Elsevier B.V.

Entities:  

Keywords:  5-aza-2′-deoxycytidine; P16 gene; bronchopulmonary dysplasia; lung interstitial fibrosis

Mesh:

Substances:

Year:  2016        PMID: 27663361     DOI: 10.1016/j.pedneo.2015.11.009

Source DB:  PubMed          Journal:  Pediatr Neonatol        ISSN: 1875-9572            Impact factor:   2.083


  7 in total

1.  5-aza-2'-deoxycytidine, a DNA methylation inhibitor, attenuates hyperoxia-induced lung fibrosis via re-expression of P16 in neonatal rats.

Authors:  Shi-Meng Zhao; Hong-Min Wu; Mei-Ling Cao; Dan Han
Journal:  Pediatr Res       Date:  2017-12-20       Impact factor: 3.756

2.  Therapeutic molecular targets of SSc-ILD.

Authors:  Yun Zhang; Jörg Hw Distler
Journal:  J Scleroderma Relat Disord       Date:  2020-01-22

Review 3.  Reactive Oxygen Species Drive Epigenetic Changes in Radiation-Induced Fibrosis.

Authors:  Shashank Shrishrimal; Elizabeth A Kosmacek; Rebecca E Oberley-Deegan
Journal:  Oxid Med Cell Longev       Date:  2019-02-06       Impact factor: 6.543

4.  Effects of fluoride on the proliferation and activation of osteoblasts by regulating methylation of the DNA repair genes MGMT and MLH1.

Authors:  Long Chen; Na Yin; Yi Ding; Mei-Lin Zhang; Min Li; Jin-Jie Zhong; Shu-Mei Feng
Journal:  Regen Ther       Date:  2022-01-30       Impact factor: 3.419

Review 5.  A broad look into the future of systemic sclerosis.

Authors:  Gabriela Riemekasten; Jörg H W Distler
Journal:  Ther Adv Musculoskelet Dis       Date:  2022-08-09       Impact factor: 3.625

Review 6.  Shared and distinct mechanisms of fibrosis.

Authors:  Jörg H W Distler; Andrea-Hermina Györfi; Meera Ramanujam; Michael L Whitfield; Melanie Königshoff; Robert Lafyatis
Journal:  Nat Rev Rheumatol       Date:  2019-11-11       Impact factor: 20.543

7.  DNA methyltransferase inhibitor suppresses fibrogenetic changes in human conjunctival fibroblasts.

Authors:  Hitomi Yonemura; Akiko Futakuchi; Miyuki Inoue-Mochita; Tomokazu Fujimoto; Eri Takahashi; Hidenobu Tanihara; Toshihiro Inoue
Journal:  Mol Vis       Date:  2019-07-21       Impact factor: 2.367

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.